N02.B3
Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis
Clinical Classification Guidelines
Medical Intelligence & Overview
Recurrent and persistent immunoglobulin A (IgA) nephropathy combined with diffuse membranoproliferative glomerulonephritis (MPGN) is a complex kidney condition characterized by ongoing inflammation and damage within the kidneys' filtering units. This condition involves the immune system producing abnormal antibodies called IgA, which deposit in the glomeruli, leading to inflammation and impaired kidney function. When accompanied by diffuse MPGN, the damage becomes more widespread, affecting the overall structure and function of the kidneys. Understanding this condition is essential for recognizing its impact on health and the importance of medical management.
Causes & Symptoms
Clinical Causes: Abnormal immune response leading to increased IgA production Genetic predisposition affecting immune regulation Chronic infections or immune system triggers that stimulate IgA production Underlying autoimmune conditions that promote immune complex deposition Environmental factors influencing immune tolerance
Key Symptoms: Blood in the urine (hematuria) Protein in the urine (proteinuria) Swelling of the legs, ankles, or face (edema) High blood pressure (hypertension) Fatigue and weakness Foamy urine due to excess protein Occasional urinary discomfort or pain Decreased urine output in advanced cases
Diagnostic & Treatment
Diagnosis Path: The diagnosis of this kidney condition involves a combination of tests. Urinalysis detects blood and protein in the urine, indicating kidney involvement. Blood tests assess kidney function through measures like serum creatinine and blood urea nitrogen (BUN). A kidney biopsy is often performed to observe the tissue under a microscope, revealing the characteristic immune deposits and glomerular changes associated with IgA nephropathy and MPGN. Imaging studies such as ultrasound may be used to evaluate kidney size and structure but are not definitive for diagnosis. Early detection through these methods is crucial for managing the progression of the disease.
Treatment Protocols: While treatments vary based on individual cases, they generally aim to slow disease progression and manage symptoms. Approaches include blood pressure control with medications such as ACE inhibitors or ARBs, which can reduce proteinuria and protect kidney function. Immunosuppressive drugs may be prescribed in cases with significant immune activity. Dietary modifications, such as reduced salt and protein intake, can help manage swelling and kidney workload. Regular monitoring of kidney function and urine analysis is important for tracking disease progression. In advanced stages, kidney replacement therapy like dialysis or transplantation may be necessary. Coordinated care with a nephrologist ensures a tailored approach to treatment and ongoing management.
Clinical Advice & FAQs
Billing Guidance
Is N02.B3 a billable ICD-10 code?
Yes, N02.B3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report N02.B3?
Clinical documentation must specify the nature of Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference